MetaCap

Cabaletta Bio (CABA) vs Scribe Therapeutics (SCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Scribe Therapeutics is the larger company by market cap ($228.6 million vs $201.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CABA-65.58%SCTX-36.37%
+104%+15%-74%
Jul 27, 20261 yearNov 20, 2026
CABA-65.07%SCTX-38.04%
+82%+5%-72%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CABA versus SCTX key metrics
MetricCABASCTX
Share price$0.9361$12.07
Market cap$201.94M$228.58M
1-day change-7.32%-8.70%
YTD return-57.26%—
1-year return-55.00%—
5-year return-91.93%—
EPS (TTM)$-1.33$-6.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-167.86M—
52-week high$4.23$39.60
52-week low$0.93$12.00
Distance from 52-week high-77.87%-69.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1155.21%+372.25%
Average volume5.15M403.27K
Shares outstanding215.72M18.94M
Employees15477
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cabaletta Bio

CABA stock →

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees

About Scribe Therapeutics

SCTX stock →

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees

CABA vs SCTX FAQ

Which is bigger, Cabaletta Bio or Scribe Therapeutics?

Scribe Therapeutics (SCTX) is larger, with a market capitalization of $228.58M compared with $201.94M for Cabaletta Bio (CABA).

Are Cabaletta Bio and Scribe Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons